Lisa Mueller, MD
Gastroenterology · Providence, RINPI 1063583383
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 61.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $10,321 and has fallen 70.6% since, to $3,031 in 2025.
Across 294 payments — averaging $86.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$16K
- Merck$3K
- AbbVie$2K
- Genentech, Inc.$1K
- Bristol Myers Squibb$682
- Takeda Pharmaceuticals U.S.A., Inc.$579
- plus $2K from 16 others
Across 60 payments — averaging $12,070 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$315K
- Takeda Pharmaceuticals U.S.A., Inc.$222K
- Eli Lilly$111K
- Genentech, Inc.$66K
- F. Hoffmann-la Roche AG$11K
What the payments were for
- Consulting fees$13,82054%
- Travel & lodging$5,36021%
- Food & beverage$6,22024%
- Gifts$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $15,585 |
| Merck | 22 | $3,165 |
| AbbVie | 134 | $1,958 |
| Genentech, Inc. | 3 | $1,434 |
| Bristol Myers Squibb | 13 | $682 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $579 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $555 |
| Johnson & Johnson | 20 | $453 |
| Lilly USA, LLC | 6 | $188 |
| Intercept Pharmaceuticals, Inc. | 7 | $167 |
| Ardelyx, Inc. | 6 | $136 |
| Ipsen Biopharmaceuticals, Inc | 6 | $135 |
| Fujifilm Healthcare Americas Corporation | 1 | $86 |
| Ferring Pharmaceuticals Inc. | 5 | $73 |
| Braintree Laboratories, Inc. | 1 | $72 |
| Gilead | 3 | $58 |
| Sanofi | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Novo Nordisk | 1 | $25 |
| QOL Medical, LLC | 1 | $25 |
| Ironwood Pharmaceuticals, Inc | 1 | $23 |
| Orphalan Inc | 1 | $19 |
How this compares
$25,471 in reported general payments places this provider in the 85th percentile of 85 gastroenterology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 967 | $14,278 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 228 | $14,224 |
| LinzessLinaclotide | 11 | $12,926 |
| Mesalamine | 17 | $11,937 |
| Famotidine | 329 | $6,785 |
| Colestipol Hcl | 26 | $5,600 |
| Pantoprazole Sodium | 290 | $4,328 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 23 | $3,611 |
| CholestyramineCholestyramine (With Sugar) | 39 | $2,637 |
| CreonLipase/Protease/Amylase | 12 | $2,464 |
| Ursodiol | 23 | $2,218 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 12 | $2,025 |
| Sucralfate | 17 | $1,725 |
| Lansoprazole | 17 | $1,446 |
| Esomeprazole Magnesium | 28 | $1,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $1,958 | $15,39023 claims |
| Braintree Laboratories, Inc.Sutab | $72 | $3,61123 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $73 | $2,02512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 85 gastroenterology providers in Rhode Island.
Other gastroenterology in Providence
- Thomas SepeProvidence$307K
- Paul AkermanProvidence$123K
- Sean FineProvidence$55K
- Breton RousselProvidence$50K
- Alan EpsteinProvidence$36K
- Samir ShahProvidence$28K
- Nabil ToubiaProvidence$20K
- Thaer AbdelfattahProvidence$17K
- Eric NewtonProvidence$16K
- William ChenProvidence$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.